Skip to main content
Premium Trial:

Request an Annual Quote

GenDx: Wietse Mulder, Maarten Penning

Wietse Mulder is stepping down as CEO of GenDx, effective July 1. Maarten Penning will lead the company as the Utrecht, Netherlands-based company's general manager and executive director of its board. Mulder will continue to support GenDx as ambassador for an undefined amount of time, mostly in marketing and communications, while representing the company at international conferences. Penning has been with GenDx for 13 years, including as chief technology officer and deputy CEO.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.